Table 1.
Baseline Characteristics by quartile of urinary CTGF concentration in the Framingham Heart Study and ARIC Study.
| Framingham Heart Study | ARIC | |||||||
|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| CTGF cut-points,* ng/ml | <1.41 | 1.41– 2.33 | 2.34 – 3.00 | ≥ 3.01 | <0.74 | 0.74–1.20 | 1.3–1.8 | ≥1.9 |
| no. of participants | 79 | 58 | 33 | 30 | 71 | 73 | 61 | 71 |
| Age* (years) | 64 +/− 7 | 64 +/− 8 | 64 +/− 6 | 63 +/− 7 | 67 +/− 5 | 65 +/− 6 | 63 +/− 6 | 63 +/− 6 |
| Women** | 55 (69.6) | 31 (53.5) | 18 (54.6) | 16 (53.3) | 31 (43.7) | 42 (57.5) | 41 (67.2) | 33 (46.4) |
| Black* | - | - | - | - | 20 (28.2) | 15 (20.5) | 13 (21.3) | 14 (19.7) |
| HTN | 42 (53.2) | 31 (53.5) | 14 (42.4) | 11 (36.7) | 41 (58.6) | 44 (61.1) | 31 (50.8) | 30 (42.2) |
| HTN Treatment | 33 (41.8) | 21 (36.2) | 10 (31.3) | 9 (30.0) | 34 (44.2) | 36 (40.9) | 18 (33.3) | 17 (29.8) |
| SBP, mmHg | 130 +/− 19 | 133 +/− 21 | 131 +/− 20 | 124 +/− 16 | 133 +/− 16 | 134 +/− 22 | 131 +/− 19 | 126 +/− 19 |
| BMI (kg/m2) | 27.2 +/− 4.9 | 27.7 +/− 4.8 | 27.0 +/− 4.1 | 29.3 +/− 4.9 | 29.2 +/− 5.7 | 28.1 +/− 5.2 | 29.0 +/− 4.8 | 27.3 +/− 4.7 |
| Diabetes | 5 (6.3) | 6 (10.3) | 2 (6.1) | 3 (10.0) | 12 (16.9) | 12 (16.4) | 11 (18.0) | 12 (16.9) |
| Current Smoking | 8 (10.1) | 5 (8.6) | 4 (12.1) | 4 (13.3) | 13 (18.3) | 5 (6.8) | 9 (14.8) | 10 (14.1) |
| HDL-cholesterol, mg/dL | 54.5 +/− 17.6 | 51.2 +/− 16.8 | 53.6 +/− 17.6 | 51.5 +/− 13.8 | 47.0 +/− 14.7 | 52.6 +/− 20.0 | 53.1 +/− 22.1 | 49.8 +/− 15.8 |
| UACR, mg/g | 6.16 (2.32, 11.35) | 3.80 (1.86, 6.67) | 4.56 (3.35, 11.08) | 3.97 (1.48, 9.60) | 3.57 (1.69, 7.84) | 3.09 (1.54, 7.85) | 4.10 (1.25, 6.67) | 3.06 (1.25, 6.67) |
| Baseline eGFR** | 84.6 +/− 23.3 | 88.0 +/− 21.8 | 93.7 +/− 31.6 | 86.2 +/− 17.4 | 83.0 +/− 15.0 | 80.9 +/− 12.1 | 82.9 +/− 14.2 | 83.5 +/− 18.3 |
| eGFR* at Follow-up | 59.3 +/− 18.3 | 64.3 +/− 17.0 | 75.1 +/− 15.7 | 74.2 +/− 17.3 | 62.5 +/− 20.9 | 62.7 +/− 25.7 | 66.5 +/− 10.7 | 59.3 +/− 18.3 |
| eGFR < 60 at follow-up | 54 (68.4) | 33 (56.9) | 8 (24.2) | 5 (16.7) | 44 (57.1) | 51 (58.0) | 20 (37.0) | 26 (45.6) |
| CTGF, ng/mL | 0.82 (0.14, 1.15) | 1.72 (1.57, 1.93) | 2.70 (2.49, 2.82) | 3.69 (3.29, 4.15) | 0.56 (0.39, 0.66) | 0.97 (0.86, 1.10) | 1.50 (1.40, 1.60) | 2.40 (2.00, 4.00) |
Data presented as mean +/− SD for normally distributed continuous variables or median (25th, 75th percentile) for continuous variables that are not normally distributed; categorical data presented as number (%). p-value for trend across quartiles. Quartiles were derived from controls only. eGFR was calculated given the 4-variable MDRD Study equation and is given in ml/min/1.73m2; factor for conversion to ml/s/1.73 m2, x0.01667.
Abbreviations: SBP: Systolic Blood Pressure; HDL: High Density Lipoprotein; eGFR: estimated glomerular filtration rate; BMI, body mass index; UACR, urinary albumin-creatinine ratio; HTN, hypertension; ARIC, Atherosclerosis Risk in Communities; CTGF, connective tissue growth factor
Quartiles were derived from controls only.
Matching characteristics: eGFR only matched in ARIC.